Share
HER3 in ovarian cancer
HER3 interacts with other HER family receptors in ovarian cancer
Preclinical research suggests the presence of HER3 interactions specific to ovarian cancer. These include4:
- Prolonged activation of the MAPK survival pathway in response to activation of both HER3 and HER4
- Activation by the ligand heregulin independent of HER2 and HER4
The clinical significance of these findings is unclear.